60 mg retatrutide Peptide 60mg (RUO) | ≥99% Purity | Research Grade | 60mg Retatrutide - 10 Vial Kit

Never discontinue prescribed autoimmune medications without direct guidance from your treating physician

more below

Women over 40 with a BMI of 27 or higher Those who have tried diet and exercise without sustained success Women experiencing perimenopausal or menopausal weight gain Those with weight related health conditions like prediabetes, type 2 diabetes, high blood pressure, or high cholesterol Women seeking significant rather than modest weight loss Those willing to commit to weekly injections for an extended period Women who can maintain adequate protein intake despite reduced appetite Certain conditions require caution or may preclude use

14 According to our patent searches, Novo Nordisk has filed 91 patents for formulations, 41 patents covering devices to deliver the drug, and 45 patents for methods of treatment (Figure 6)

If everything goes as planned, the FDA could approve orforglipron in 2026